Name | Adelmidrol |
Synonyms | NSC 27132 AdelMitrol Adelmidrol N,N'-Bis(2-hydroxyethyl)nonanediamide N1,N9-bis(2-hydroxyethyl)-nonanediamide Nonanediamide, N1,N9-bis(2-hydroxyethyl)- |
CAS | 1675-66-7 |
Molecular Formula | C13H26N2O4 |
Molar Mass | 274.36 |
Density | 1.097±0.06 g/cm3(Predicted) |
Melting Point | 132-134℃ |
Boling Point | 596.4±45.0 °C(Predicted) |
Solubility | DMSO: ≥ 34 mg/mL |
pKa | 14.19±0.10(Predicted) |
Storage Condition | 2-8°C |
In vitro study | Adelmidrol is a palmitoylethanolamide analogue. Adelmidrol reduces NF-κB translocation, COX-2, and p-ERK expression; proinflammatory cytokine release; and the incidence of nitrotyrosine and poly(ADP)ribose in the colon. |
In vivo study | Adelmidrol (10 mg/kg, o.s.) reduces significantly the degree and severity of the macroscopic and histologic signs of colon injury. Moreover, 4 days after colitis induced by dinitrobenzene sulfonic acid (DNBS) treatment, all mice have diarrhea and a reduction in body weight (compared with the sham groups). Adelmidrol (10 mg/kg, o.s.) treatment significantly reduces the loss of body weight. The inflammatory bowel disease (IBD) induced by DNBS intrarectally administered is also characterized by an augmentation in myeloperoxidase (MPO) activity, an indicator of neutrophil accumulating in the colon. This is consistent with light microscopic observations showing the colon of vehicle-treated DNBS mice to contain a large number of neutrophils. In contrast, Adelmidrol (10 mg/kg, o.s.) significantly reduces the degree of polymorphonuclear cell infiltration (determined as reduction in MPO activity) in inflamed colon. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.645 ml | 18.224 ml | 36.449 ml |
5 mM | 0.729 ml | 3.645 ml | 7.29 ml |
10 mM | 0.364 ml | 1.822 ml | 3.645 ml |
5 mM | 0.073 ml | 0.364 ml | 0.729 ml |
biological activity | ademidrol is an analog of cetamide ethanol (PEA) with anti-inflammatory activity. |